Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Slides:

Advertisements

Similar presentations

Health Strategies Group

Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

PrEP: A Case-by-Case Approach

The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer

Advances in Managing Inhibitors in Patients With Hemophilia A

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

Patient-Centered Care in Cystic Fibrosis

Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

Current and Future Goals in the Treatment of Relapsed CLL

Goals of Therapy in Relapsed CLL

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Clinical Considerations in Evidence-based Management of GIST

Novel and Emerging Approaches to Treating CLL

The Nurse View.

Management Challenges in CLL

Updates in Lymphoma From Recent Congresses

Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Evaluating Next-Generation BTK Inhibitors

Navigating New Oral Treatment Algorithms in CLL

Targeting BTK Signaling in B-Cell Malignancies

Managing Adverse Events With New Oral Therapies in CLL

Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL

Optimizing Outcomes and Managing Adverse Events in CLL

Poor Response to Initial Therapy for Migraine

Personalized Therapy in Relapsed or Refractory CLL

Interprofessional Approaches: Managing AEs of Novel Therapies for NHL/CLL.

Improving Outcomes in Psoriatic Arthritis

Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.

CMV in the HSCT Recipient

Understanding and Addressing the Needs of Patients With AD

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

Non-Chemotherapy Combinations in CLL

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Patient Questions and Expert Answers in Psoriasis:

A Guideline-Based Approach to HCV Care

Evaluating BTK Inhibitors in CLL

Are We Making Progress in the Management of Huntington Disease?

Insulin in Diabetes Management: Effective Patient Selection Is Key

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

Optimizing Joint Health in Hemophilia

Assessing New Paradigms in CLL: MRD Negativity

FDA-Approved PI3K Inhibitors for CLL and FL

Challenges in LA SCCHN.

Managing CLL With BTK Inhibitors

First-Line FCR: Effect of del(17p) on PFS and OS

Improving Adherence to Antiplatelet Therapy After an ACS Event

The Patient With Early Stage MF-CTCL

Oral Treatment Strategies in CLL

Educational Objectives

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

Oral Therapies in MS.

Transitioning Therapy in PAH: Practical Strategies and Considerations

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Clinical Considerations in Evidence-based Management of GIST

How to Select Therapy in Relapsed/Refractory CLL

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Evaluating the Totality of Evidence

New Options for the Treatment of Hepatocellular Carcinoma

Changing Paradigms in Relapsed/Refractory Indolent NHL

Ask the Psoriasis Expert

Treatment Initiation and Selection in Newly Diagnosed CLL

Uncovering the Right Sequence

Utilizing MRD Assessment in Community Practice

Presentation transcript:

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL

Content Outline

Stakeholders in Managing Adverse Events of CLL Therapies

Concerning Specific Toxicities of Ibrutinib

Managing Infections While on Ibrutinib

Other Ibrutinib-Related Side Effects

When to Substitute Acalabrutinib

Headaches Are a Specific Concern for Patients on Acalabrutinib

Strategies to Enhance Treatment Adherence

Role of PI3K Inhibitors in CLL With Progression

Keys for Effective PI3K Inhibitor Use

Emerging Role of Venetoclax in CLL Therapy

Other Venetoclax-Associated Adverse Events

Managing Venetoclax-Associated Neutropenia

Concluding Remarks

Abbreviations

Abbreviations (cont)